<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682524</url>
  </required_header>
  <id_info>
    <org_study_id>DW_PlbCR_401</org_study_id>
    <nct_id>NCT02682524</nct_id>
  </id_info>
  <brief_title>Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blinded, parallel, active-controlled, phase IV clinical&#xD;
      trial to evaluate the efficacy and safety of PlbCR and aceclofenac in the treatment of&#xD;
      patients with osteoarthritis of the knee&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline 100mm Pain VAS at 4weeks</measure>
    <time_frame>4weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline 100mm Pain VAS at 2weeks</measure>
    <time_frame>2weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline K-WOMAC Scale at 2weeks and 4weeks</measure>
    <time_frame>2weeks, 4weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>4weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Osteoarthritis of Knee</condition>
  <arm_group>
    <arm_group_label>test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelubiprofen CR 45mg tab.</intervention_name>
    <arm_group_label>test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aceclofenac 100mg tab.</intervention_name>
    <arm_group_label>reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  both male and female who is over 35year-old and below 80year-old&#xD;
&#xD;
          -  patient who diagnosed as Kellgren &amp; Lawrence stage I~III by X-ray&#xD;
&#xD;
          -  osteoarthritis patient who is stable within 3months form starting this clinical trial&#xD;
&#xD;
          -  patient who is over 40mm in 100mm Pain VAS at Visit 2&#xD;
&#xD;
          -  patient who agreed to participate this clinical trial spontaneously&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  second osteoarthritis&#xD;
&#xD;
          -  patient who has inflammatory disease which can effect efficacy outcomes such as&#xD;
             bursitis, tenosynovitis, rheumatoid arthritis, etc.&#xD;
&#xD;
          -  patient who diagnosed as gastric ulcer or GI disease by esophagogastroduodenoscopy&#xD;
&#xD;
          -  patient who had joint surgery within 12months form screening visit of this clinical&#xD;
             trial or planned to operate in this clinical trial period&#xD;
&#xD;
          -  patient who has had artificial joint surgery of knee&#xD;
&#xD;
          -  malignant tumor patient&#xD;
&#xD;
          -  patient who has taken Psychopharmaceutical or Narcotic Analgesics over 3months&#xD;
             continuously&#xD;
&#xD;
          -  patient who took steroid by oral, inhalation or intraarticular injection within&#xD;
             3months form screening visit of this clinical trial&#xD;
&#xD;
          -  patient who took intraarticular hyaluronic acid injection of knee within 2months form&#xD;
             screening visit of this clinical trial&#xD;
&#xD;
          -  patient who cannot take NSAIDs because of disease or medicine&#xD;
&#xD;
          -  allergy of aspirin of other NSAIDs&#xD;
&#xD;
          -  patient who has to handle his/her pain by or for CABG&#xD;
&#xD;
          -  galactose intolerance, Lactose Intolerance or glucose-galactose malabsorption&#xD;
&#xD;
          -  inflammatory bowel disease such as ulcerative colitis or Crohn's disease&#xD;
&#xD;
          -  moderate renal disease&#xD;
&#xD;
          -  moderate hepatic disease&#xD;
&#xD;
          -  moderate hypertension(SBP=&gt;160mmHg, DBP=&gt;100mmHg)&#xD;
&#xD;
          -  female who consents to contracept&#xD;
&#xD;
          -  patient who is not appropriate for this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inha university hospital</name>
      <address>
        <city>Chung gu</city>
        <state>Incheon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aceclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

